16 August 2021 | News
Non-invasive, easy to administer way to enhance oral bioavailability and efficacy of Visceral Leishmaniasis therapy
image credit- shutterstock
A group of researchers at the Institute of Nano Science and Technology (INST), Mohali has developed a non-invasive, easy to administer, cost-effective, and patient compliant potential therapeutic strategy against Visceral Leishmaniasis, a neglected tropical disease.
Their strategy based on nano carrier-based oral drugs coated with Vitamin B12 enhanced oral bioavailability and efficacy of the therapy by more than 90%.
Visceral Leishmaniasis (VL) is a complex infectious disease transmitted by the bite of female Phlebotomine sandflies. It is a neglected tropical disease that affects millions annually, making it the second most common parasitic killer after malaria.
The researchers have developed a smart and intelligent nanocarrier utilizing the natural intrinsic Vitamin B12 pathway present in human body that can mitigate stability challenges and drug-associated toxicity.
They have disguised the toxic but highly efficient drug of the disease within a biocompatible lipid nanocarrier shielding it from degradation in the hostile gastric environment, thus overcoming the gastrointestinal enzymatic barriers endured by any foreign synthetic drug molecule.
Anchoring Vitamin B12 on the surface of solid lipid nanoparticles augmented the stability and targeted delivery of the poorly soluble drugs and also enhanced the therapeutic efficiency with reduced risks of off-target actions.